This is a preview of subscription content, log in via an institution to check access.
Notes
Funded by Genentech, Inc., with which some of the researchers were affiliated.
Reference
Boudreau DM, et al. Cost-Effectiveness of Recombinant Tissue-Type Plasminogen Activator Within 3 Hours of Acute Ischemic Stroke: Current Evidence. Stroke : 4 Sep 2014. Available from: URL: http://doi.org/10.1161/STROKEAHA.114.005852
Rights and permissions
About this article
Cite this article
Tenecteplase a cost-saving early option for acute ischaemic stroke. PharmacoEcon Outcomes News 712, 31 (2014). https://doi.org/10.1007/s40274-014-1576-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1576-6